NeuroOne Medical Technologies Corporation reported its financial results for the three months ending December 31, 2025, revealing a significant decline in revenue and an increase in net losses compared to the same period in 2024. The company generated product revenue of $2.9 million, down from $3.3 million in the prior year, primarily due to a lack of license revenue, which had contributed $3 million in the previous year. The gross profit from product sales was $1.6 million, reflecting a gross margin of 54.2%, compared to a gross profit of $1.9 million and a margin of 58.9% in the same quarter of 2024.
Total operating expenses for the quarter increased slightly to $3.3 million from $3.2 million year-over-year. This increase was driven by higher research and development costs, which rose to $1.4 million from $1.2 million, attributed to consulting services and materials for new applications. Selling, general, and administrative expenses decreased to $1.9 million from $2.0 million, primarily due to reduced legal and professional service fees. The company reported a net loss of $1.4 million for the quarter, a stark contrast to the net income of $1.8 million reported in the same quarter of the previous year.
In terms of operational metrics, NeuroOne's cash and cash equivalents decreased to approximately $3.6 million as of December 31, 2025, down from $6.6 million at the end of the previous quarter. The company’s total assets also declined to $8.6 million from $10.8 million, while total liabilities decreased significantly to $2.2 million from $3.7 million, largely due to a reduction in accounts payable and accrued expenses. The company’s employee headcount remained stable, with no significant changes reported.
Strategically, NeuroOne initiated a limited market release of its OneRF TN Ablation System in December 2025, which is expected to enhance its product offerings. The company has also entered into a distribution agreement with Zimmer, Inc., which is anticipated to bolster its market presence. However, the company faces challenges, including reliance on a single customer for 100% of its product revenue during the quarter, highlighting a significant concentration risk.
Looking ahead, NeuroOne expressed concerns regarding its ability to continue as a going concern, citing the need for additional funding to support operations and product development. The company plans to utilize its current cash reserves and revenue from product sales while seeking further capital through equity or debt financing. The management indicated that without successful fundraising or improved operational results, it may need to reduce planned expenditures to extend its operational runway.
About NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies develops advanced thin film electrode technology for diagnosing and treating neurological disorders such as epilepsy, Parkinson’s disease, dystonia, and chronic pain. Its core products include cortical and sEEG electrodes, ablation systems, and stimulation devices, primarily targeting the U.S. market. The company focuses on minimally invasive solutions, integrated diagnostic and therapeutic tools, and leveraging scalable manufacturing to improve clinical outcomes and reduce procedural risks.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.